News Sentiment

AMLX sentiment intelligence

Amylyx Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 52 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 17.77 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

82/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-2.7% over one week, +21.8% over four weeks, trend active, and materially above fair value.

Latest direct headline Negative

Trade Alert: Chief Legal Officer & General Counsel Of Amylyx Pharmaceuticals Gina Mazzariello Has Sold Stock

Market Reaction

Balanced read

61/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 82/100 classification
One-week reaction -2.7% Price reacting lower
Trend fit Trend active 21.8% over four weeks
Fair value 81.5% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 11
Neutral 34
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
TradingView 6
Stock Titan 5
simplywall.st 5
Market source 5
Quartr 3
Finviz 3
Moomoo 3
www.marketscreener.com 3

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 7
Analyst action 5
Regulatory and legal 3
Balance sheet 2
Deals and strategy 1
Guidance 1
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 52
Simply Wall Street Direct company coverage

Trade Alert: Chief Legal Officer & General Counsel Of Amylyx Pharmaceuticals Gina Mazzariello Has Sold Stock

Gina Mazzariello, Chief Legal Officer & General Counsel of Amylyx Pharmaceuticals (NASDAQ:AMLX), recently sold US$539k worth of stock at US$17.96 per share, reducing her holding by 47%. This sale was the largest insider sale for the company in the last year, suggesting caution de

Tone
Negative 35/100
Event
Market update
Published
15 Jul 2026 11:48
Source
Simply Wall Street
Stock Titan Direct company coverage

Amylyx Pharmaceuticals (AMLX) CLO sells 30,000 shares under 10b5-1 plan

Amylyx Pharmaceuticals' Chief Legal Officer, Gina Mazzariello, sold a total of 30,000 common shares in two open-market transactions on July 9 and July 10, 2026. The sales were conducted under a Rule 10b5-1 trading plan adopted on April 9, 2026. Following these transactions, Mazza

Tone
Negative 36/100
Event
Market update
Published
13 Jul 2026 19:40
Source
Stock Titan
Quartr Direct company coverage

Amylyx Pharmaceuticals (AMLX) Proxy filing Summary

Amylyx Pharmaceuticals (AMLX) has scheduled its Annual Meeting for June 4, 2026, to be held virtually, with proxy materials available online. Key agenda items include the election of two Class II directors, ratification of Deloitte & Touche LLP as the independent registered publi

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 00:12
Source
Quartr
Investing.com Nigeria Direct company coverage

Form 144 Amylyx Pharmaceuticals For: 9 July By Investing.com

This article from Investing.com reports on the filing of Form 144 by Amylyx Pharmaceuticals on July 9, 2026. Form 144 is typically used to notify the SEC of the intent to sell restricted securities. The brief article provides the date of the filing and mentions Amylyx Pharmaceuti

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 21:50
Source
Investing.com Nigeria
Stock Titan Direct company coverage

[144] Amylyx Pharmaceuticals, Inc. SEC Filing

This article details an SEC Form 144 filing by Amylyx Pharmaceuticals, Inc. (AMLX). The filing indicates a proposed sale of 30,000 common shares with an aggregate market value of $536,400. The shares were acquired on March 31, 2025, as Restricted Stock Units from the issuer, with

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 20:04
Source
Stock Titan
Quartr Direct company coverage

Amylyx Pharmaceuticals (AMLX) M&A Announcement Summary

Amylyx Pharmaceuticals (AMLX) has acquired avexitide for $35.1 million in cash, aiming to expand its pipeline into rare endocrine and metabolic diseases beyond neurodegenerative conditions. The acquisition aligns with the company's focus on high unmet medical needs like hyperinsu

Tone
Positive 72/100
Event
Deals and strategy
Published
09 Jul 2026 01:39
Source
Quartr
Quartr Direct company coverage

Amylyx Pharmaceuticals (AMLX) Q3 2024 earnings summary

Amylyx Pharmaceuticals (AMLX) reported its Q3 2024 earnings, highlighting a strategic shift towards its advanced late-stage pipeline following the discontinuation of RELYVRIO/ALBRIOZA. The company is focusing on AMX0035 for Wolfram syndrome and PSP, and avexitide for PBH, which w

Tone
Neutral 50/100
Event
Earnings
Published
08 Jul 2026 23:39
Source
Quartr
Finviz Direct company coverage

AMLX - Amylyx Pharmaceuticals Inc Dividends

This article provides detailed financial data for Amylyx Pharmaceuticals Inc (AMLX), including its market performance, key financial ratios, and insider/institutional ownership. It highlights the company's stock price, market capitalization, income, sales, and various performance

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 09:42
Source
Finviz
Moomoo Direct company coverage

Companies Like Amylyx Pharmaceuticals (NASDAQ:AMLX) Are In A Position To Invest In Growth

This article analyzes Amylyx Pharmaceuticals (NASDAQ:AMLX) and discusses its financial position to invest in growth. The company has a substantial cash reserve and minimal debt, providing flexibility for strategic investments. Key financial metrics such as cash runway, enterprise

Tone
Positive 68/100
Event
Balance sheet
Published
03 Jul 2026 10:40
Source
Moomoo
Finviz Direct company coverage

AMLX - Amylyx Pharmaceuticals Inc Latest SEC Filings

This article provides detailed financial data and stock performance metrics for Amylyx Pharmaceuticals Inc (AMLX) as of July 2, 2026. It includes information on market capitalization, income, sales, P/E ratios, insider and institutional ownership, and year-to-date performance. Th

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 21:10
Source
Finviz
Finviz Direct company coverage

AMLX - Amylyx Pharmaceuticals Inc Earnings

This article provides a detailed financial overview of Amylyx Pharmaceuticals Inc (AMLX). It includes key metrics such as market capitalization, sales, earnings per share, insider and institutional ownership, and various performance indicators. The data indicates recent positive

Tone
Neutral 50/100
Event
Earnings
Published
02 Jul 2026 18:09
Source
Finviz
Insider Monkey Direct company coverage

Is Amylyx Pharmaceuticals, Inc. (AMLX) Stock Ready for a Breakout Ahead of Key LUCIDITY Trial Data?

Amylyx Pharmaceuticals (AMLX) is being eyed for a potential breakout, with Guggenheim raising its price target to $40 and upgrading it to a "Best Idea" ahead of Q3 LUCIDITY trial results for avexitide. The company also presented positive Phase 1 LUMINA trial data for AMX0114 in A

Tone
Positive 71/100
Event
Earnings
Published
30 Jun 2026 13:09
Source
Insider Monkey
The National Law Review Direct company coverage

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) on behalf of investors who purchased securities before November 11, 2022, and still hold them. The investigation seeks to determine if Amylyx and its officers

Tone
Negative 18/100
Event
Regulatory and legal
Published
30 Jun 2026 10:40
Source
The National Law Review
TradingView Direct company coverage

AMLX Forecast — Price Target — Prediction for 2027

This article provides a forecast for Amylyx Pharmaceuticals, Inc. (AMLX) stock, including analyst price targets, past performance, and future earning estimations. It states that analysts have a maximum price target of $40.00 and a minimum of $19.00, with the stock previously reac

Tone
Neutral 50/100
Event
Analyst action
Published
30 Jun 2026 00:40
Source
TradingView
www.marketscreener.com Direct company coverage

Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell Microcap Value Benchmark Index

Amylyx Pharmaceuticals, Inc. (NasdaqGS:AMLX) has been removed from the Russell Microcap Value Benchmark Index. This news follows previous announcements earlier the same day regarding its removal from other Russell indexes including the Small Cap Comp Value, Microcap, 3000 Value,

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 16:40
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell Small Cap Comp Value Benchmark

Amylyx Pharmaceuticals, Inc. (NasdaqGS:AMLX) has been removed from the Russell Small Cap Comp Value Benchmark, as reported by S&P Capital IQ. This news follows several other recent announcements that the company has been dropped from various Russell indices, including the Microca

Tone
Negative 36/100
Event
Market update
Published
29 Jun 2026 10:40
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Amylyx Pharmaceuticals, Inc.(NasdaqGS: AMLX) dropped from Russell Microcap Index

Amylyx Pharmaceuticals, Inc. (NasdaqGS: AMLX) has been removed from the Russell Microcap Index, as announced on June 29, 2026. This news follows several other recent removals from various Russell indices, including the Russell 3000E Index and Russell Microcap Value Benchmark Inde

Tone
Negative 36/100
Event
Market update
Published
29 Jun 2026 05:45
Source
www.marketscreener.com
marketscreener.com Direct company coverage

Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell 2500 Value Benchmark

Amylyx Pharmaceuticals, Inc. (NasdaqGS:AMLX) has been removed from the Russell 2500 Value Benchmark. The company is a clinical-stage pharmaceutical firm focusing on four investigational therapies, including avexitide for Post-Bariatric Hypoglycemia and congenital HI, AMX0035 for

Tone
Negative 38/100
Event
Regulatory and legal
Published
28 Jun 2026 21:11
Source
marketscreener.com
Insider Monkey Direct company coverage

12 Best Low-Priced Pharma Stocks to Buy Right Now

This article identifies Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) as one of the best low-priced pharma stocks to consider. Guggenheim recently raised its price target for AMLX to $40 and reaffirmed a Buy rating, elevating it to a "Best Idea" ahead of anticipated Phase 3 trial re

Tone
Positive 72/100
Event
Analyst action
Published
28 Jun 2026 12:40
Source
Insider Monkey
TradingView Direct company coverage

Price to sales forward of Amylyx Pharmaceuticals, Inc. – NASDAQ:AMLX

This article displays the "Price to sales forward" metric for Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) on TradingView. It indicates that the market is closed, and no trades have occurred for this particular data point. The page provides a snapshot of financial data for the com

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 21:40
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Amylyx Pharmaceuticals, Inc. – NASDAQ:AMLX

The article focuses on the enterprise value to EBIT forward for Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX). It indicates that this financial metric is a key focus for investors tracking the company. The content appears to be a stub or a section from a financial data platform, hi

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 21:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Amylyx Pharmaceuticals, Inc. – NASDAQ:AMLX

This article provides the enterprise value to revenue forward for Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX). It indicates that the market was closed at the time of the information display and includes general financial data and market information related to the company on Tradi

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 03:10
Source
TradingView
ALS News Today Direct company coverage

Amylyx advancing ALS treatment in trial after early safety data is positive

Amylyx's investigational ALS therapy, AMX0114, is progressing to higher doses in the LUMINA Phase 1 clinical trial after initial safety data showed it was well-tolerated at the lowest dose. While biomarkers of nerve damage remained stable at this dose, researchers believe higher

Tone
Positive 71/100
Event
Regulatory and legal
Published
26 Jun 2026 19:10
Source
ALS News Today
TradingView Direct company coverage

Enterprise value to EBITDA forward of Amylyx Pharmaceuticals, Inc. – NASDAQ:AMLX

The article is a financial data page from TradingView focusing on the Enterprise Value to EBITDA forward for Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX). It indicates that the market was closed and no trades were made when the data was accessed, presenting the company's financial

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 13:09
Source
TradingView
TradingView Direct company coverage

Amylyx Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:AMLX)

This article provides financial actuals and estimates for Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX), covering its stock performance, analyst forecasts, and company financials. Key details include current stock price, historical highs and lows, market capitalization, and upcoming

Tone
Positive 66/100
Event
Analyst action
Published
26 Jun 2026 07:09
Source
TradingView